CYP3A7

Cytochrome P450 3A7

33,446 patent compounds predicted against CYP3A7, 25,967 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Telithromycin (SCHEMBL5100)	1.00	6/20
Telithromycin (SCHEMBL5101)	1.00	6/20
Telithromycin (SCHEMBL784845)	1.00	6/20
SCHEMBL784787	0.76	3/20
SCHEMBL971260	0.42	3/20
SCHEMBL971261	0.40	3/20
SCHEMBL84978	0.84	2/20
SCHEMBL84543	0.79	2/20
SCHEMBL196765	0.73	2/20
SCHEMBL784963	0.72	2/20
SCHEMBL84929	0.70	2/20
SCHEMBL84985	0.70	2/20
SCHEMBL85532	0.69	2/20
SCHEMBL84517	0.69	2/20
SCHEMBL84914	0.68	2/20
SCHEMBL84919	0.68	2/20
SCHEMBL85531	0.68	2/20
SCHEMBL84994	0.68	2/20
SCHEMBL85018	0.65	2/20
SCHEMBL85133	0.62	2/20

Germline variants in CYP3A7 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CYP3A7 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CYP3A7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Physiological Study of the Human CYP3A Activity (PiSA)	PHASE4	COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.	PHASE4	RECRUITING
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab	PHASE2	RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).	PHASE2	UNKNOWN
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer	PHASE2	COMPLETED
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients	PHASE2	RECRUITING
A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer	PHASE1	COMPLETED
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060	PHASE1	COMPLETED
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors	PHASE1	RECRUITING
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults	PHASE1	COMPLETED
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients	PHASE1	COMPLETED
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer	PHASE1	RECRUITING
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Optimisation of Nutrition and Medication for Acutely Admitted Older Medical Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP3A7 binder may also engage these)

Protein	Name	Similarity
O18993	—	1.000	O18993 →
Q64464	—	1.000	Q64464 →
CYP3A5	Cytochrome P450 3A5	1.000	landscape →
P33268	—	1.000	P33268 →
Q29496	—	1.000	Q29496 →
Q64481	—	1.000	Q64481 →
O09158	—	1.000	O09158 →
P79401	—	1.000	P79401 →
Q8AXY5	—	1.000	Q8AXY5 →
P05183	—	1.000	P05183 →
P11707	—	1.000	P11707 →
CYP3A4	Cytochrome P450 3A4	1.000	landscape →
P79102	—	1.000	P79102 →
Q64406	—	1.000	Q64406 →
P04800	—	1.000	P04800 →
Q64459	—	1.000	Q64459 →
P51538	—	1.000	P51538 →
P24463	—	1.000	P24463 →
Q64581	—	1.000	Q64581 →
Q9PVE8	—	0.999	Q9PVE8 →
Q98T91	—	0.998	Q98T91 →
Q64417	—	0.997	Q64417 →
O42563	—	0.997	O42563 →
O70537	—	0.996	O70537 →
CYP3A43	Cytochrome P450 3A43	0.995	landscape →
Q64148	—	0.995	Q64148 →
Q64409	—	0.994	Q64409 →
Q9JMA7	—	0.992	Q9JMA7 →
Q964R0	—	0.985	Q964R0 →
Q27593	—	0.983	Q27593 →